Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncolo…
$21.02+0.53%
报价 2026-11-09
市值
$686.2M
EV
$541.9M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -26.3%
$5.81$28.53
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-09不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NVCTNuvectis Pharma, Inc. | $686.2M | +0.5% | -87.0% | 0% | – | – | – | |
| CGENCompugen Ltd. | $202.7M | +9.2% | – | 86.9% | 7.6x | 7.5x | – | |
| IPHAInnate Pharma S.A. | $164.9M | +4.9% | – | 100% | – | – | – | |
| ARMPArmata Pharmaceuticals, Inc. | $141.3M | +8.3% | +13.3% | 68.2% | – | – | – | |
| MOLNMolecular Partners AG | $118.5M | -3.9% | – | 0% | – | – | – | |
| MISTMilestone Pharmaceuticals Inc. | $91.9M | -3.3% | – | 94.6% | – | – | – | |
| TNXPTonix Pharmaceuticals Holding Corp. | $77M | -5.3% | +189.4% | 52.6% | – | – | – | |
| CRDFCardiff Oncology, Inc. | $62.3M | +0.7% | -40.0% | 100% | – | – | – | |
| RANIRani Therapeutics Holdings, Inc. | $37.5M | +5.0% | -13.5% | 96.7% | – | – | – | |
| 同行中位数 | – | – | -0.1% | 90.7% | 7.6x | 7.5x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
电话会纪要摘要
暂无纪要摘要。